Pretraga
Rezultati
Phase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R) [2015]
Thongprasert, Sumitra; ...; Jovanovic, D; ...; Petrovic, M; ...; Radosavljevic, Davorin Z; Perin, Branislav M; ...; (broj, koautora 19)Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 [2020]
Grivas, P; ...; Radulovic, Sinisa S; ...; (broj, koautora 20)Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [2010]
Eckel, F; Brunner, T; Jelic, Svetislav BComprehensive overview of norms, quality, and use of evidence-based recommendation in oncology in low-and middle income countries: The CONQUER study [2025]
Sharma, K; ...; Calamac, MD; ...; (broj, koautora 18)Influence of VEGF expression on response to therapy with EGFR inhibitor in patients with EGFR negative liver metastases from colorectal carcinoma [2006]
Petrović, Zora; Tarabar, DinoDoubts and dilemmas during the process of setting up adequate indications for conservative breast cancer treatment
[2005]
Vukotić, Đorđe; Šašić, Miomir; Petković, Đorđe; Buta, Marko Incomplete liver resection plus chemotherapy in patients with metastatic colorectal cancer (CRC) decrease survival in comparison to chemotherapy alone [2005]
Popov, IvanDoes HER2 status of the primary breast cancers influence time to late relapse? [2009]
Tomašević, ZoricaHER-2 status of the primary breast cancer in patients with late disease relapse
[2006]
Tomašević, Zorica Analyses of oxidative stress parameters in the sera of breast cancer patients [2005]
Jurišić, VladimirФилтери
По типу
- 315